Khanmammadov, N. Et Al. 2023. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).

Khanmammadov, N., DOĞAN, İ., Saip, P., & Aydiner, A., (2023). Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America

Khanmammadov, Nıjat Et Al. "Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2023

Khanmammadov, Nıjat Et Al. "Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2023

Khanmammadov, N. Et Al. (2023) . "Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.

@conferencepaper{conferencepaper, author={Nıjat KHANMAMMADOV Et Al. }, title={Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2023}}